Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
CA 2452039 A1 · Owner: Elan Pharmaceuticals, Inc. · Inventors: Hom, Roy; Tucker, John; John, Varghese
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to substituted alcohol compounds of the formula (I) wherein X, R1, R2, R3, RN, R20 et RC are defined herein. The compounds are useful in the treatment or prevention of Alzheimer's disease and more specifically to compounds that are capable of inhibiting beta-secretase an , enzyme that cleaves amyloid precursor protein to produce amyloid beta peptide (A-beta), a major component of the amyloid plaques found in the brains of Alzhaimer's sufferers.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 27, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 27, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 27, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.